341
Views
1
CrossRef citations to date
0
Altmetric
Special Section: Selected Articles from the ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop 2020 - Lead and Impact: Turning Innovation into Practice

Our Most Important Discovery: The Question

Pages 398-407 | Received 23 Jan 2021, Accepted 15 Aug 2021, Published online: 11 Oct 2021
 

Abstract

It is healthy to periodically question things that we have long taken for granted. Randomized clinical trials are the gold standard for evaluating the benefits and harms of interventions, though often fails to provide the practical evidence to inform medical decision-making. A primary reason is failure to recognize the most important questions for treating patients in clinical practice, and using this as the motivation for the design, monitoring, analysis, and reporting of clinical trials. Our most promising opportunity is placing increased interest on questions of a pragmatic origin to match their clinical importance. Improvements to traditional approaches are needed. Standard approaches synthesizing information obtained from separate marginal analysis of each outcome, fail to incorporate associations between outcomes and recognize the cumulative nature of outcomes in individual patients, suffer from competing risk complexities during interpretation of individual outcomes, and since efficacy and safety analyses are often conducted on different populations, generalizability is unclear. The utility of clinical trials can be enhanced by: (i) using outcomes to analyze patients rather than patients to analyze the outcomes, and (ii) incorporating benefit:risk evaluation into standard trial design and conduct, rather than conducted as a post-hoc exercise. Benefit: risk outcomes such as the desirability of outcome ranking (DOOR), can become a standard, prespecified along with efficacy and safety outcomes. Inclusion and analyses of such endpoints provide important information regarding the effects on patients, unable to be obtained by marginal analyses of efficacy and safety. Prespecified procedures to identify subgroups of patients with a positive benefit:risk profile will further advance clinical trial science.

Funding

The author(s) reported there is no funding associated with the work featured in this article.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 61.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 71.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.